Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia™) for the prevention of emesis and motion sickness in cats

Journal of Veterinary Pharmacology and Therapeutics

Volumn 31, Issue 3, 2008, Pages 220-229

  Hickman, M A ^a   Cox, S R ^a   Mahabir, S ^a   Miskell, C ^a   Lin, J ^a   Bunger, A ^a   McCall, R B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAROPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; MALE; MOTION SICKNESS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREMOR; VOMITING;

ANIMALS; CATS; FEMALE; MALE; METABOLIC CLEARANCE RATE; MOTION SICKNESS; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 43549084998     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.00952.x     Document Type: Article

References (27)

1. Andrew, P.L.R. Bhandari, P. (1993) Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology, 32, 799 806.
2. Ariumi, H., Saito, R., Nago, S., Hyakusoku, M., Takano, Y. Kamiya, H.-O. (2000) The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neuroscience Letters, 286, 123 126.
3. Benchaoui, H.A., Cox, S.R., Schneider, R.P., Boucher, J.F. Clemence, R.G. (2007a) The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. Journal of Veterinary Pharmacology and Therapeutics, 30, 336 344.
4. Benchaoui, H.A., Siedek, E.M., De la Puente-Redondo, V.A., Tilt, N., Rowan, T.G. Clemence, R.G. (2007b) Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Veterinary Record, 161, 444 447.
5. Bhandari, P. Andrew, P.L.R. (1992) Resinferatoxin: a braod spectrum anti-emetic in the ferret. In Mechanisms and Control of Emesis. Eds Bianchi, A.L., Grelot, L., Miller, A.D. King, G.L., pp. 239 240. INSERM/John Libbey Eurotext, Montrouge.
6. Bountra, C., Bunce, K., Dale, T., Gardner, C., Jordan, C., Twissell, D. Ward, P. (1993) Antiemetic profile of a nonpeptide neurokinin NK1 receptor antagoinist, CP 99994 in ferrets. European Journal of Pharmacology, 249, R3 R4.
7. Brizzee, K.R. (1990) The central nervous connections involved in motion induced emesis. In Motion and Space Sickness. Ed. Crampton, G.H., pp. 9 28. CRC Press, Boca Raton, USA.
8. Crampton, G.H. Lucot, J.B. (1985) A stimulator for laboratory studies of motion sickness in cats. Aviation Space and Environmental Medicine, 56, 462 465.
9. TM), in the treatment of ongoing emesis caused by a variety of underlying clinical aetiologies in canine patients in Europe. The Journal of Small Animal Practice, 48, 93 98.
10. De la Puente-Redondo, V.A., Tilt, N., Rowan, T.G. Clemence, R.G. (2007b) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. American Journal of Veterinary Research, 68, 48 56.
11. De la Puente-Redondo, V.A., Tingley, F.D. III., Schneider, R.P. Hickman, M.A. (2007c) The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model. Journal of Veterinary Pharmacology and Therapeutics, 30, 281 374.
12. Gardner, C.J., Bountra, C., Bunce, K.T., Dale, T.J., Jordan, C.C., Twissell, D.J. Ward, P. (1994) Anti-emetic activity of neurokinin NK receptor antagonists is mediated centrally in the ferret. British Journal of Pharmacology, 112, 516P.
13. Hargreaves, R. (2002) Imaging substance P receptors (NK-1) in the living human brain using positron emission tomography. The Journal of Clinical Psychiatry, 63 (Suppl. 11 18 24.
14. 3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat. Pharmacology, Biochemistry and Behavior, 32, 207 210.
15. Lucot, J.B., Obach, R.S., McLean, S. Watson, J.W. (1997) The effect of CP-99994 on the responses to provocative motion in the cat. British Journal of Pharmacology, 120, 116 120.
16. McLean, S. (1996) Nonpeptide antagonists of the NK-1 tachykinin receptor. Medicinal Research Reviews, 16, 297 317.
17. Miller, A.D. Ruggiero, D.A. (1994) Emetic reflex are revealed by expression of the immediate-early gene c-fos in the cat. Journal of Neuroscience, 14, 871 888.
18. Miller, A.D., Nonaka, S. Jakus, J. (1994) Brain areas essential or non-essential for emesis. Brain Research, 647, 255 264.
19. Patel, L. Lindley, C. (2003) Aprepitant - a novel NK-1-receptor antagonist. Expert Opinion Pharmacotherapy, 4, 2279 2296.
20. TM) an NK-1 antagonist for preventing motion sickness in dogs. Journal of Veterinary Pharmacology and Therapeutics. in press.
21. Rupniak, N.M. Kramer, M.S. (1999) Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK-1) antagonist. Trends in Pharmacological Sciences, 20, 485 490.
22. Saria, A. (1999) The tachykinin NK-1 receptor in the brain: pharmacology and putative functions. European Journal of Pharmacology, 375, 51 60.
23. Kahn, C.M. (ed. 2005) The Merck Veterinary Manual, 9th edn, pp. 1047. Merck Publishing Group, Rahway, NJ.
24. TM) in a randomized clinical trial for prevention and treatment of cisplatin induced emesis in dogs presented as veterinary patients. Veterinary & Comparative Oncology, 5, 38 46.
25. Von Euler, U.S. Gaddum, J.H. (1931) An unidentified depressor substance in certain tissue extracts. Journal of Physiology, 72, 74 87.
26. Watson, J.W., Gonsalves, S.F., Fossa, A.A., McLean, S., Seeger, T., Obach, S. Andrews, P.L.R. (1995) The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK-1 receptor. British Journal of Pharmacology, 115, 84 94.
27. Zajonc, T.P. Roland, P.S. (2006) Vertigo and motion sickness. Part ll: pharmacologic treatment. Ear Nose and Throat, 85, 25 35.